Recce Pharmaceuticals Announces The Pew Charitable Trusts' Addition of Recce's Lead Compound RECCE(R) 327 to List of Antibiotic Treatments in Clinical Development

MLA

“Recce Pharmaceuticals Announces The Pew Charitable Trusts’ Addition of Recce’s Lead Compound RECCE(R) 327 to List of Antibiotic Treatments in Clinical Development.” GlobeNewswire, 15 Mar. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.655000462&authtype=sso&custid=ns315887.

APA

Recce Pharmaceuticals Announces The Pew Charitable Trusts’ Addition of Recce’s Lead Compound RECCE(R) 327 to List of Antibiotic Treatments in Clinical Development. (2021, March 15). GlobeNewswire.

Chicago

GlobeNewswire. 2021. “Recce Pharmaceuticals Announces The Pew Charitable Trusts’ Addition of Recce’s Lead Compound RECCE(R) 327 to List of Antibiotic Treatments in Clinical Development,” March 15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.655000462&authtype=sso&custid=ns315887.